Accueil
Marchés
Graphique & Idées
Algo
Nouvelles
Store
Courtiers
Télécharger
Calendrier Economique
Signaux de trading
Terminal Web
Heatmap
Tapez
/
pour rechercher : @user, $symbol
Recherche
Se connecter
Créer un compte
Français
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Italiano
Türkçe
RLMD
#2648
Relmada Therapeutics, Inc. Common Stock
7.1
8
USD
-0.14%
Secteur:
Soins de Santé
Base:
USD
Devise de Profit:
USD
Range quotidien
Range Annuel
Changement quotidien
-0.14%
Changement Mensuel
+20.07%
Evolution sur 6 mois
+246.86%
Changement Annuel
+2293.33%
Clôture Précédente
7.1
9
Open
7.1
0
Bid
Ask
Low
7.0
8
High
7.2
1
Volume
600
Marchés
Actions des Marchés US
Soins de Santé
RLMD
Open full chart
Financials
Overview
Relevé
Statistics
Quarterly
Annual
Value
Q4, 24
Q1, 25
Q2, 25
Q3, 25
Q4, 25
TTM
Key stats
Total common shares outstanding
33.19 M
33.19 M
33.19 M
73.33 M
104.89 M
—
Valuation ratios
Enterprise value
13.4 M
7.81 M
18.57 M
146.02 M
503.12 M
675.52 M
Price to earnings ratio
-0.2
-0.11
-0.27
-1.12
-3.33
-4.83
Price to sales ratio
41.84
21.2
61.6
840.01
-2 407.45
-1 484.64
Price to cash flow ratio
-0.3
-0.14
-0.37
-1.57
-4.16
-6.25
Price to book ratio
0.44
0.05
0.15
0.75
2.2
3.15
Enterprise value to EBITDA ratio
—
—
—
—
—
—
Profitability ratios
Return on assets %
-0.41
-0.63
-0.47
-0.68
-0.21
-1.99
Return on equity %
-0.53
-0.78
-0.62
-1.07
-0.23
-2.7
Return on invested capital %
—
—
—
—
-392.2 K
—
Gross margin %
100
100
100
100
100
400
Operating margin %
-46.7 K
-28.94 K
-21.65 K
12.68 K
18.84 K
-19.07 K
EBITDA margin %
—
—
—
—
—
—
Net margin %
-45.68 K
-27.89 K
-20.9 K
12.39 K
18.41 K
-17.99 K
Liquidity ratios
Quick ratio
—
—
—
—
—
—
Current ratio
4.45
5.29
4.11
2.86
14.62
26.87
Inventory turnover
—
—
—
—
—
—
Asset turnover
0
0
0
-0
-0
-0
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
Long term debt to total assets ratio
—
—
—
—
—
—
Long term debt to total equity ratio
—
—
—
—
—
—
Per share metrics
Operating cash flow per share
-0.29
-0.59
-0.19
-0.2
-0.37
-1.36
EBIT per share
-0.63
-0.6
-0.31
-0.31
-0.52
-1.73
EBITDA per share
—
—
—
—
—
—
Total debt per share
—
—
—
—
—
—
Cash per share
1.49
0.89
0.62
0.42
2.36
4.29
Net current asset value per share
1.52
0.91
0.64
0.45
2.38
4.37
Tangible book value per share
1.18
0.74
0.48
0.29
2.19
3.69
Working capital per share
1.18
0.74
0.48
0.29
2.22
3.73
Book value per share
1.18
0.74
0.48
0.29
2.19
3.69
Nouvelles
Does Relmada Therapeutics (RLMD) Have the Potential to Rally 75.58% as Wall Street Analysts Expect?
Mizuho réitère sa notation sur l’action Relmada suite aux progrès des essais de Phase 3
Relmada Therapeutics: 2 New Assets, 2 New 'Blockbusters'? I'd Wait And See (NASDAQ:RLMD)
Comment l’analyse de la Juste Valeur a détecté le gain de 65% de Relmada en 2024
Piper Sandler initie la couverture de Relmada Therapeutics avec une note Surpondération
Mizuho relève l’objectif de cours de Relmada Therapeutics suite aux données d’essai
Relmada Therapeutics, Inc. (RLMD) Q4 2025 Earnings Call Transcript
Alerte résultats Relmada Therapeutics T4 2025 : BPA manqué, action stable
Mizuho réitère sa recommandation sur Relmada après des données positives sur le cancer
Mizuho reiterates Relmada stock rating on positive cancer trial data
RLMD Stock Surges 42% in a Week: Here's What You Should Know
Avago, Lumentum among market cap stock movers on Monday